Shanghai AQ BioPharma Co., Ltd.

Shanghai AQ BioPharma was found on 2007 in Zhangjiang Pharmaceutical Valley, the company is the national "Thousand Talents Plan" special experts, National Natural Science Second prize winner, Chinese Overseas Chinese Contribution Award winner, Shanghai excellent technology leader as the core. A management team with senior experience in new drug innovation research and development, international market development and international trade has been formed by a number of overseas doctors. The team has a lot of core technology in the pharmaceutical field as well as domestic and foreign market experience and entrepreneurial experience. The company currently has 12 shareholders including Shanghai Science Venture Capital. The company specializes in the research and development of fluorine-containing new drugs and the production of fluorine-containing new drug intermediates. It is a leading fluorine-containing pharmaceutical technology company and a fluorine-containing pharmaceutical technology platform in China. At present, the company's fluorine-containing pharmaceutical intermediate products project has the international advanced level, and 30% of the process and products have the international advanced level. The subsidiary of the company will be awarded the "National High-tech Enterprise" in 2021. At present, the company has completed the engineering process of a number of projects in the pilot stage, and the 51 mu industrialization base with an investment of nearly 120 million has been completed. This year, the company will start large-scale production and realize the one-stop innovation and entrepreneurship in the field of fluorine medicine. The company won the "2009 most dynamic Shanghai Technology Enterprise"; In 2010, he won the second Prize of the Second Shanghai Invention and Innovation Competition. In 2012, he won the fourth Overseas Chinese Contribution Award (innovative achievement); In 2012, he won the "Science and Technology Innovation Award" of Shanghai Zhangjiang Hi-Tech Park. The company has completed a number of national, provincial and municipal science and technology projects such as the Ministry of Science and Technology and Shanghai SME Technology Innovation Fund projects. The company's products have helped more than a dozen new drug development enterprises to enter the clinical phase I to III. At present, the company is developing at a fast speed from the development and production of fluorine medicine technology to the research and development of fluorine containing new drugs. The company has applied for 27 invention patents and authorized 15. In 2020, the company and Shanghai University of Technology jointly build the first "Shanghai Green Fluoropharmaceutical Engineering Technology Research Center"; The company's ongoing projects in the field of fluorine new drug research and development include: fluorine anti-tumor new drug research and development project; Fluorine-containing anti-AIDS drug research and development project; Research and development project of new fluorine-containing lipid-lowering drugs, and research and development project of fluorine-containing antifungal drugs.